Cue Biopharma, Inc. Announces Major Board Changes and Committee Restructuring

Boston, MA – June 2, 2026 – Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company, has made significant announcements regarding changes to its Board of Directors and committee structures, which may have important implications for shareholders and could potentially affect the company’s share price.

Key Developments

• Resignation of Four Directors:
  • On May 29, 2026, four members of Cue Biopharma’s Board of Directors – Jill Broadfoot, Peter Kiener, Frank Morich, and Patrick Verheyen – mutually agreed with the Company to resign from their positions as board members and from all Board committees, effective immediately.
  • This represents a significant turnover in the Board, which investors should note as it could indicate a shift in strategic direction or governance priorities at the company.
• Appointment of New Directors:
  • Simultaneously, the Company announced the appointment of two new directors:
    • Daniel Camardo
    • Viola Meehan
  • Both new directors bring substantial experience. Ms. Meehan, in particular, has a background in finance leadership at major pharmaceutical companies, including significant roles at AbbVie Inc. and a career start at Price Waterhouse Coopers LLP. She holds a Bachelor’s in Accounting from the Wharton School and an MBA in Finance from the University of Chicago.
  • Mr. Camardo’s experience and background details were not fully outlined in this filing, but his appointment as both a director and a committee chair indicates a high level of confidence from the Board.
• Committee Restructuring:
  • The Board has reconstituted its principal committees following the appointments:
    • Audit Committee: Viola Meehan (Chair), Daniel Camardo, Pamela Garzone
    • Compensation Committee: Pamela Garzone (Chair), Daniel Camardo, Viola Meehan
    • Nominating and Corporate Governance Committee: Daniel Camardo (Chair), Pasha Sarraf
  • This restructuring places the new directors in key leadership positions within the board’s governance framework.
• Director Compensation and Indemnification:
  • Mr. Camardo and Ms. Meehan will receive cash and equity compensation for their service as directors, in accordance with the Company’s Director Compensation Policy, as detailed in the proxy statement for the 2026 annual meeting and filed with the SEC.
  • Both new directors will enter into Cue Biopharma’s standard form of indemnification agreement, under which the Company may be required to indemnify them for certain expenses related to their service as directors, including legal fees and settlements.

Potential Impact on Shareholders and Share Price

• Significant Board Turnover:
  • The simultaneous departure of four directors and the addition of two new members (who are immediately taking on committee leadership roles) represents a major shift in corporate governance. Such changes can be interpreted by the market as either a sign of positive new direction or potential instability, depending on the context and communication from the company.
• Leadership and Strategic Direction:
  • With the new board composition, investors should closely monitor upcoming communications from Cue Biopharma regarding its strategic priorities, pipeline updates, and any changes in corporate strategy that may arise from the new leadership.
• Director Compensation and Indemnification:
  • The details regarding director compensation and indemnification are standard for public companies but are important for transparency and governance best practices.

Other Details

• The company’s common stock continues to be listed on the Nasdaq Capital Market under the symbol “CUE.”
• The company is incorporated in Delaware, with its principal executive offices at 40 Guest Street, Boston, MA 02135.
• Cue Biopharma’s President and Chief Executive Officer, Shao-Lee Lin, signed the report as both the Principal Executive Officer and interim Principal Financial and Accounting Officer.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult with their financial advisors before making investment decisions. The information provided here is based on the company’s official SEC filing as of June 2, 2026, and may be subject to further updates or clarifications by Cue Biopharma, Inc. The author and publisher are not responsible for any actions taken based on this article.

View Cue Biopharma, Inc. Historical chart here